Astellas Pharma Inc., a Japanese drug-maker, has been active in several areas within the biotech sector. The company entered into a research collaboration and license agreement with Poseida Therapeutics to accelerate the development of unique cell therapies. With the unveiling of its new $90 million state-of-the-art Innovation Center situated in the South San Francisco Biotech hub, Astellas aims to foster collaboration and drive scientific advances. However, the firm faced disappointment as it fell below analysts' earnings expectations. Astellas received some positive news with the FDA's approval of its combination therapy for bladder cancer. The company could not secure approval for their gastric cancer drug, but earned approval for a gastric cancer antibody in Japan. Astellas made significant movements in the market as it completed the acquisition of Propella Therapeutics, and announced its plans to acquire the same. However, the company had a legal setback when it failed to block generic Myrbetriq amidst the patent suit. Also, Astellas secured an agreement to take over Propella Therapeutics for $175m. Furthermore, the company received permanent J-code for IZERVAY™, a treatment for Geographic Atrophy. On the innovation front, the company has been proactive in patient centricity and AI, and has run successful digital campaigns, which have positively impacted patients.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Thu, 09 May 2024 10:44:26 GMT -
Rating 2
- Innovation 4
- Information 6
- Rumor -2
